CFDE Data Portal | Search NEPRO-AS1

	Label	Description
	NEPRO-AS1 Gene (Entity type)	ENSG00000240057 - NEPRO antisense RNA 1
	GSE119978 GSE180930 cisplatin 6 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE196035 GSE196037 MEN1 inhibition 3 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE230329 0 V 3 DEXTRAN MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE173201 0 V 1 CISPLATIN HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE197555 trametinib A-549 NCI-H460 1 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE207410 GSE207411 ARID1A knockdown 1 v 6 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE115542 digoxin 2 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE190384 GSE190386 fulvestrant 1 v 8 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE92364 0 V 5 ASPARAGINASE MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS

NEPRO-AS1

ENSG00000240057 - NEPRO antisense RNA 1

GSE119978 GSE180930 cisplatin 6 v 7 human dn

A Gene Set from LINCS

GSE196035 GSE196037 MEN1 inhibition 3 v 7 human up

A Gene Set from LINCS

GSE230329 0 V 3 DEXTRAN MOUSE UP

A Gene Set from LINCS

GSE173201 0 V 1 CISPLATIN HUMAN UP

A Gene Set from LINCS

GSE197555 trametinib A-549 NCI-H460 1 v 2 human dn

A Gene Set from LINCS

GSE207410 GSE207411 ARID1A knockdown 1 v 6 human up

A Gene Set from LINCS

GSE115542 digoxin 2 v 0 human up

A Gene Set from LINCS

GSE190384 GSE190386 fulvestrant 1 v 8 human up

A Gene Set from LINCS

GSE92364 0 V 5 ASPARAGINASE MOUSE UP

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.